Denna sida på svenska

Katalin Dobra

Senior lecturer/senior physician

Visiting address : F56, Karolinska Universitetssjukhuset 14186 Stockholm, Sweden
Postal address : Department of Laboratory Medicine (LABMED), H5, Division of Pathology, F46, Karolinska Universitetssjukhuset, Huddinge 141 86 Stockholm, Sweden
Delivery address : F56 Via Varumottagningen, Karolinska Universitetssjukhuset 14186 Stockholm, Sweden

Publications

18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas
Uhlén N, Grundberg O, Jacobsson H, Sundin A, Dobra K, Sánchez-crespo A, et al
Clinical nuclear medicine 2016;41(4):263-7

Comments on the recently published "Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma"
Hjerpe A, Dobra K
Cancer cytopathology 2015;123(8):449-53

Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma
Ötvös R, Szulkin A, Hillerdal Co, Celep A, Yousef-fadhel E, Skribek H, et al
Genes & cancer 2015;6(3-4):119-28

Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
Hjerpe A, Ascoli V, Bedrossian C, Boon M, Creaney J, Davidson B, et al
CytoJournal 2015;12():26-

Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication
Hjerpe A, Ascoli V, Bedrossian Cw, Boon Me, Creaney J, Davidson B, et al
Cytopathology : official journal of the British Society for Clinical Cytology 2015;26(3):142-56

Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
Hjerpe A, Ascoli V, Bedrossian Cw, Boon Me, Creaney J, Davidson B, et al
Acta cytologica 2015;59(1):2-16

Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
Hjerpe A, Ascoli V, Bedrossian Cw, Boon Me, Creaney J, Davidson B, et al
Diagnostic cytopathology 2015;43(7):563-76

Impact of Extracellular Matrix on Cellular Behavior: A Source of Molecular Targets in Disease
Skandalis Ss, Dobra K, Götte M, Karousou E, Misra S
BioMed research international 2015;2015():482879-

Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma
Heidari-hamedani G, Vivès Rr, Seffouh A, Afratis Na, Oosterhof A, Van Kuppevelt Th, et al
Cellular signalling 2015;27(10):2054-67

Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma (vol 27, pg 2054, 2015)
Heidari-hamedani G, Vives Rr, Seffouh A, Afratis Na, Oosterhof A, Van Kuppevelt Th, et al
CELLULAR SIGNALLING 2015;27(12):2599-2600

Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication
Szatmári T, Ötvös R, Hjerpe A, Dobra K
Disease markers 2015;2015():796052-

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions
Szulkin A, Otvös R, Hillerdal Co, Celep A, Yousef-fadhel E, Skribek H, et al
BMC cancer 2014;14():709-

Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies
Mundt F, Heidari-hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K
BioMed research international 2014;2014():419853-

Nuclear translocation of heparan sulfate proteoglycans and their functional significance
Kovalszky I, Hjerpe A, Dobra K
Biochimica et biophysica acta 2014;1840(8):2491-7

Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma
Mundt F, Johansson Hj, Forshed J, Arslan S, Metintas M, Dobra K, et al
Molecular & cellular proteomics : MCP 2014;13(3):701-15

Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma
Mundt F, Nilsonne G, Arslan S, Csürös K, Hillerdal G, Yildirim H, et al
PloS one 2013;8(8):e72030-

Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma
Darai-ramqvist E, Nilsonne G, Flores-staino C, Hjerpe A, Dobra K
Frontiers in oncology 2013;3():203-

The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors
Szatmári T, Dobra K
Frontiers in oncology 2013;3():310-

Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy
Szulkin A, Nilsonne G, Mundt F, Wasik Am, Souri P, Hjerpe A, et al
PloS one 2013;8(6):e65903-

Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma
Røe Od, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T, et al
PloS one 2012;7(8):e40521-

Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells
Szatmári T, Mundt F, Heidari-hamedani G, Zong F, Ferolla E, Alexeyenko A, et al
PloS one 2012;7(10):e48091-

Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2
Péterfia B, Füle T, Baghy K, Szabadkai K, Fullár A, Dobos K, et al
PloS one 2012;7(6):e39474-

Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells
Enqvist M, Nilsonne G, Hammarfjord O, Wallin Rpa, Bjorkstrom Nk, Bjornstedt M, et al
JOURNAL OF IMMUNOLOGY 2011;187(7):3546-54

Specific Syndecan-1 Domains Regulate Mesenchymal Tumor Cell Adhesion, Motility and Migration
Zong F, Fthenou E, Mundt F, Szatmari T, Kovalszky I, Szilak L, et al
PLOS ONE 2011;6(6):e14816-

Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas
Skandalis Ss, Labropoulou Vt, Ravazoula P, Likaki-karatza E, Dobra K, Kalofonos Hp, et al
BMC CANCER 2011;:314-

Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions
Flores-staino C, Darai-ramqvist E, Dobra K, Hjerpe A
LUNG CANCER 2010;68(1):39-43

Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains
Zong F, Fthenou E, Castro J, Peterfia B, Kovalszky I, Szilak L, et al
CELL PROLIFERATION 2010;43(1):29-40

Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration
An Zw, Dobra K, Lock Jg, Stromblad S, Hjerpe A, Zhang Hq
INTERNATIONAL JOURNAL OF CANCER 2010;127(9):1999-2008

Chondroitin Sulfate A Regulates Fibrosarcoma Cell Adhesion, Motility and Migration through JNK and Tyrosine Kinase Signaling Pathways
Fthenou E, Zong F, Zafiropoulos A, Dobra K, Hjerpe A, Tzanakakis Gn
IN VIVO 2009;23(1):69-76

Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, et al
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2009;:92-

Syndecan-1 and FGF-2, but Not FGF Receptor-1, Share a Common Transport Route and Co-Localize with Heparanase in the Nuclei of Mesenchymal Tumor Cells
Zong F, Fthenou E, Wolmer N, Hollosi P, Kovalszky I, Szilak L, et al
PLOS ONE 2009;4(10):e7346-

Malignant mesothelioma - A connective tissue tumor with proteoglycan-dependent differentiation
Hjerpe A, Dobra K
CONNECTIVE TISSUE RESEARCH 2008;49(3-4):249-51

Targeted Therapy - Possible new therapeutic option for malignant mesothelioma?
Dobra K, Hjerpe A
CONNECTIVE TISSUE RESEARCH 2008;49(3-4):270-2

Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells
Rundlof Ak, Fernandes Ap, Selenius M, Babic M, Shariatgorji M, Nilsonne G, et al
DIFFERENTIATION 2007;75(2):123-32

Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells
Sun Xj, Gulyas M, Hjerpe A, Dobra K
CANCER LETTERS 2006;232(2):161-9

Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress
Nilsonne G, Sun X, Nystrom C, Rundlof Ak, Fernandes Ap, Bjornstedt M, et al
FREE RADICAL BIOLOGY AND MEDICINE 2006;41(6):874-85

Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro
Theocharis Ad, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, et al
JOURNAL OF BIOLOGICAL CHEMISTRY 2006;281(46):35116-28

Targeting thioredoxin reductase - a possible new treatment for malignant mesothelioma
Nilsonne G, Stein A, Rundlof Ak, Fernandes Ap, Bjornstedt M, Hjerpe A, et al
LUNG CANCER 2006;:S52-S52

Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling
Sun Xj, Wei L, Liden J, Hui G, Dahlman-wright K, Hjerpe A, et al
JOURNAL OF PATHOLOGY 2005;207(1):91-101

A sandwich ELISA for the estimation of human syndecan-2 and syndecan-4 in biological samples
Seidel C, Gulyas M, David G, Dobra K, Theocharis Ad, Hjerpe A
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 2004;34(4):797-801

DIFFERENTIAL EFFECTS OF SELENITE ON MALIGNANT MESOTHELIOMA CELLS- A NOVEL THERAPEUTIC APPROACH RELATED TO THE Trx-TrxR SYSTEM AND THE REDOX STATE OF THE CELLS
Nilsonne G, Sun Xj, Nystrom C, Rundlof Ak, Nurminen M, Bjornstedt M, et al
ANTICANCER RESEARCH 2004;24(5D):3473-3473

Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells
Liu Zw, Dobra K, Hauzenberger D, Klominek J
ANTICANCER RESEARCH 2004;24(2B):599-603

Growth factors regulate the expression profile of their syndecan Co-receptors and the differentiation of mesothelioma cells
Dobra K, Nurminen M, Hjerpe A
ANTICANCER RESEARCH 2003;23(3B):2435-44

Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: Tubulin-dependent rearrangements
Brockstedt U, Dobra K, Nurminen M, Hjerpe A
EXPERIMENTAL CELL RESEARCH 2002;274(2):235-45

Synthesis and expression of mRNA encoding for different versican splice variants is related to the aggregation of human epithelial mesothelioma cells
Syrokou A, Dobra K, Tzanakakis Gn, Hjerpe A, Karamanos Nk
ANTICANCER RESEARCH 2002;22(6C):4157-62

An optimized battery of eight antibodies that can distinguish mast gases at epithelial mesothelioma from adenocarcinoma
Brockstedt U, Gulyas M, Dobra K, Dejmek A, Hjerpe A
AMERICAN JOURNAL OF CLINICAL PATHOLOGY 2000;114(2):203-9

Differentiation of mesothelioma cells is influenced by the expression of proteoglycans
Dobra K, Andang M, Syrokou A, Karamanos Nk, Hjerpe A
EXPERIMENTAL CELL RESEARCH 2000;258(1):12-22

Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells
Sun Xj, Dobra K, Bjornstedt M, Hjerpe A
DIFFERENTIATION 2000;66(4-5):181-8

Expression of genes coding for proteoglycans and Wilms' tumour susceptibility gene 1 (WT1) by variously differentiated benign human mesothelial cells
Gulyas M, Dobra K, Hjerpe A
DIFFERENTIATION 1999;65(2):89-96

Show all publications